Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers
暂无分享,去创建一个
E. Kaempgen | V. Lennerz | A. Knuth | L. von Boehmer | A. Ochsenbein | U. Forssmann | N. Mach | D. Hess | S. Gross | E. Gallerani | U. Gnad-Vogt | S. Böhm | T. Woelfel
[1] C. Britten,et al. The role of the reporting framework MIATA within current efforts to advance immune monitoring. , 2014, Journal of immunological methods.
[2] C. Sessa,et al. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors , 2014, Cancer Immunology, Immunotherapy.
[3] M. Sata,et al. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. , 2013, Developmental and comparative immunology.
[4] J. Wolchok,et al. Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients , 2013, Cancer Immunology Research.
[5] T. Treasure,et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Akira Yamada,et al. Next‐generation peptide vaccines for advanced cancer , 2013, Cancer science.
[7] Morten Nielsen,et al. Characterizing the binding motifs of 11 common human HLA‐DP and HLA‐DQ molecules using NNAlign , 2012, Immunology.
[8] H. Rammensee,et al. Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients , 2012, International journal of cancer.
[9] J. Becker,et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.
[10] Ö. Türeci,et al. Tumor vaccination using messenger RNA: prospects of a future therapy. , 2011, Current opinion in immunology.
[11] P. Hwu,et al. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. , 2011, Vaccine.
[12] O. Lund,et al. Identification of MHC class II restricted T‐cell‐mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides , 2011, Immunology.
[13] O. Lund,et al. HLA Class I Binding 9mer Peptides from Influenza A Virus Induce CD4+ T Cell Responses , 2010, PloS one.
[14] Sylvia Janetzki,et al. "MIATA"-minimal information about T cell assays. , 2009, Immunity.
[15] D. Speiser,et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. , 2009, Cancer research.
[16] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[17] O. Lantz,et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.
[18] D. Speiser,et al. Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers1 , 2006, The Journal of Immunology.
[19] R. Day,et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer , 2005, Cancer Immunology, Immunotherapy.
[20] Y. Iwamoto,et al. In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide 1 , 2004, The Journal of Immunology.
[21] Heidemarie Neitzel,et al. A routine method for the establishment of permanent growing lymphoblastoid cell lines , 1986, Human Genetics.
[22] Urs Christen,et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.
[23] J. Becker,et al. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. , 2001, Cancer research.
[24] R. Schreiber,et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .
[25] R. Schreiber,et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[27] V. Engelhard,et al. Structure of peptides associated with class I and class II MHC molecules. , 1994, Annual review of immunology.